within the cardiovascular landscape. This
review focuses on “immuno-miRs,” a class of mi
Beylerli, Ozal,
Gareev, Ilgiz,
Musaev, Elmar,
Roumiantsev, Sergey,
Chekhonin, Vladimir,
Ahmad, Aamir,
Chao, Yuan,
Yang, Guang (2025) for innovative precision therapies. This
review examines the current state of targeted therapies for intracranial
as a potential treatment for FTD. Finally, a
review of the current scientific literature identified 13
and may present novel opportunities for therapeutic intervention. This
review aims to provide a